Kamal Ramzipoor, President and Chief Executive Officer
Mr. Ramzipoor is the president and chief executive officer of Amaranth Medical, Inc. He oversees all aspects of the company’s operations, including research and development, global manufacturing operations, regulatory, clinical and finance. Kamal has spent more than 28 years developing products and technologies for the medical device industry.
Prior to co-founding Amaranth, he served as the director of the ischemic stroke franchise for the Neurovascular Division of Boston Scientific Corporation (BSC), where he was responsible for developing and managing a portfolio of “best in class” intravascular devices for the treatment of stroke. Before joining BSC, he was chief technology officer and vice president of research and development at Micrus Endovascular Corporation (acquired by Johnson & Johnson). Mr. Ramzipoor’s previous positions include senior director of research and development at Acuson Corporation (acquired by Siemens) and director of research and development at Progressive Angioplasty Systems (acquired by US Surgical).
Earlier in his career, Mr. Ramzipoor held various engineering and management positions at Guidant and BSC. Prior to entering the medical device field, he spent several years in the aerospace industry, developing polymer-based, high-strength composites for a variety of applications. Mr. Ramzipoor received his BS in Mechanical Engineering from the Detroit Institute of Technology and is an inventor and author on more than 100 US patents and publications.
Jane Beggs, Senior Vice President of Regulatory, Clinical and Quality
Ms. Beggs is the senior vice president of regulatory, clinical and quality at Amaranth Medical, Inc. With more than 25 years of experience in the medical device industry, Ms. Beggs has obtained regulatory approvals for the clinical study and commercialization of medical products in the US, Europe, Australia, Canada and Japan. In earlier roles at Advanced Cardiovascular Systems-Guidant and Perclose-Abbott, she defined strategies for pre-clinical testing, clinical studies, quality systems and all aspects of the regulatory pathway. More recently, Ms. Beggs has held various leadership positions at venture-backed start-ups, leading to approvals for devices for gastrointestinal endoscopy (stenting and gastroplasty), spinal decompression and laser dermatology.
Ms. Beggs has a bachelor’s degree in biology from the University of California, Berkeley and an MBA (finance emphasis) from the Notre Dame de Namur University, Belmont, CA.
Edward (Alex) Estrada, Vice President, Research & Development
Mr. Estrada is vice president of research and development for Amaranth Medical, Inc., and has more than 30 years of experience working with medical devices. Before joining the company, he was vice president, research and development, at NovoStent Corporation, a medical device start-up company developing a novel Nitinol stent for the superficial femoral artery (SFA). Previously, Mr. Estrada spent 19 years within the Advanced Cardiovascular Systems/Guidant/Abbott Vascular organizations, most recently as director of research and development for the endovascular division of Abbott. He has been instrumental in developing a drug eluting stent for the SFA as well as the first carotid stent to receive FDA approval.
Mr. Estrada has been an inventor on numerous patents and patent applications. He holds a BS in mechanical engineering from California Polytechnic State University at San Luis Obispo.
Anthony Andreacchi, Ph.D., Vice President, Operations
Dr. Andreacchi serves as vice president of operations for Amaranth Medical, Inc. He has over 20 years of experience in the medical device field, and has worked for Abbott Vascular, Guidant, Lifescan (Johnson & Johnson), and STS Biopolymers (acquired by Angiotech). Immediately prior to joining Amaranth, Dr. Andreacchi was senior manager of research and development at Abbott Vascular. There he managed the advanced drug-eluting stent programs, drug-coated balloons for coronary and peripheral treatments, stent development and process engineering, and the test method development teams. At Guidant, Dr. Andreacchi developed the manufacturing process for the ML™ Vision stent and subsequently all their cobalt-chromium-based stents. He was instrumental in the technical development of the Xience™ V drug-eluting stent, and has managed the pilot-scale and manufacturing operations at Guidant and STS, respectively.
Dr. Andreacchi holds more than 30 US and international patents in the areas of drug-coated balloons, drug-coated stents, medical device coating equipment, automation, and stent electropolishing. Dr. Andreacchi graduated from Arizona State University with a BSE in biomedical engineering, and holds MS and Ph.D. degrees in chemical engineering from the University of Rochester (NY).